GRIMES & Co WEALTH MANAGEMENT LLC Buys 5,167 Shares of Becton, Dickinson and Company $BDX

GRIMES & Co WEALTH MANAGEMENT LLC raised its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 352.7% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 6,632 shares of the medical instruments supplier’s stock after buying an additional 5,167 shares during the period. GRIMES & Co WEALTH MANAGEMENT LLC’s holdings in Becton, Dickinson and Company were worth $1,187,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. BlackRock Inc. acquired a new stake in shares of Becton, Dickinson and Company in the 2nd quarter worth approximately $3,721,533,000. State Street Corp increased its stake in shares of Becton, Dickinson and Company by 8.5% during the second quarter. State Street Corp now owns 15,000,064 shares of the medical instruments supplier’s stock valued at $2,269,960,000 after acquiring an additional 1,177,256 shares during the period. First Eagle Investment Management LLC increased its stake in shares of Becton, Dickinson and Company by 15.8% during the second quarter. First Eagle Investment Management LLC now owns 13,815,335 shares of the medical instruments supplier’s stock valued at $2,090,675,000 after acquiring an additional 1,887,224 shares during the period. Bank of America Corp DE bought a new stake in Becton, Dickinson and Company during the second quarter worth approximately $474,993,000. Finally, Legal & General Group Plc raised its holdings in Becton, Dickinson and Company by 1.5% during the second quarter. Legal & General Group Plc now owns 2,101,695 shares of the medical instruments supplier’s stock worth $318,050,000 after purchasing an additional 30,766 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors.

Becton, Dickinson and Company Trading Down 0.4%

Shares of NYSE:BDX opened at $197.88 on Wednesday. The stock has a market capitalization of $54.52 billion, a price-to-earnings ratio of 15.28, a PEG ratio of 13.39 and a beta of 0.22. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $200.47. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87. The company has a 50 day moving average price of $186.86 and a 200 day moving average price of $170.20.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.14 by $0.09. The firm had revenue of $4.98 billion for the quarter, compared to analyst estimates of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The firm’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, research analysts anticipate that Becton, Dickinson and Company will post 12.67 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on BDX. Bank of America increased their price target on Becton, Dickinson and Company from $185.00 to $200.00 and gave the company a “neutral” rating in a research note on Monday, August 31st. Barclays initiated coverage on Becton, Dickinson and Company in a research note on Wednesday, October 7th. They issued an “underweight” rating and a $165.00 price objective on the stock. Citigroup restated a “buy” rating on shares of Becton, Dickinson and Company in a report on Thursday, August 13th. TD Cowen raised their target price on Becton, Dickinson and Company from $163.00 to $182.00 and gave the company a “hold” rating in a research note on Wednesday, August 5th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $210.00 target price on shares of Becton, Dickinson and Company in a research note on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $185.07.

Insider Transactions at Becton, Dickinson and Company

In related news, CEO Thomas Polen, Jr. sold 4,152 shares of Becton, Dickinson and Company stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $185.00, for a total value of $768,120.00. Following the transaction, the chief executive officer directly owned 110,163 shares in the company, valued at $20,380,155. The trade was a 3.63% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of Becton, Dickinson and Company stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total value of $440,887.92. Following the completion of the transaction, the executive vice president owned 14,856 shares in the company, valued at $2,686,559.04. The trade was a 14.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 6,907 shares of company stock valued at $1,269,128 in the last three months. 0.40% of the stock is currently owned by corporate insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD’s products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.